PAP 9704, a traditional prescription of Korea (Polygala tenuifola : Acorus gramineus : Poria cocosϭ1 : 1 : 1) has been used in the clinical treatment for the neurodegenerative conditions, such as amnesia and dementia. 1) We have demonstrated that PAP 9704 possesses a protective effect in response to neurotoxicity induced by kainate.
and behavioral side effects. 4) In our preliminary study, we have observed that PAP 9704 exhibits Panax ginseng-like sedative-and anti-psychotropic effects. 5) Therefore, we attempted to investigate whether PAP 9704 could prevent MAinduced hyperlocomotion in this study.
The purine nucleotide adenosine might act as a neuromodulator of the CNS and an endogenous neuroprotectant. 6) Adenosine exerts its effects on the neuronal activity via four G protein-coupled receptors, A 1 , A 2A , A 2B and A 3 .
7) While adenosine A 1 and A 2B receptors are widely distributed in the brain, the A 2A receptor distribution is restricted to the dopamine-innervated regions. 8) A 3 receptors are expressed at low levels in the brain. Stimulation of either A 1 or A 2A receptors induces a psychomotor depression and counteracts the motor activating effects of dopamine receptor agonists. 9) Adenosine analogs have also been found to decrease striatal dopamine turnover and dopamine release. 10) This antagonistic adenosine-dopamine interaction in the striatum seems to be mediated by either presynaptic A 1 receptors or postsynaptic A 2A receptors, co-localized with D 2 dopamine receptors in striatopallidal neurons. 11) Transcription factors encoded by the Fos and Jun families of immediate early genes have been studied as potential mediators of drug-induced neural plasticity. [12] [13] [14] [15] The acute administration of psycho-stimulants produces a rapid but transient induction of several Fos-and Jun-like proteins in the striatal complex. In contrast, chronic drug exposure desensitizes the ability of these proteins to be induced and results instead in the gradual accumulation of a novel Fos-like protein termed chronic Fos-related antigen (FRA) protein. 12, 13) Recent work has definitively identified the chronic FRA as an isoform of D-Fos B.
13) Therefore, it is thought that FRA induction is, in part, relevant to various behavioral features of prolonged cocaine exposure. [12] [13] [14] [15] We evaluated the impact of PAP 9704 on the MA-induced behavioral effects and expression of the striatal fos-related antigen-immunoreactivity (FRA-IR) to learn whether adenosine receptors play a role in the pharmacological effects of PAP 9704, since adenosine A 1 and A 2A receptors regulates dopaminergic neuronal activity as described above.
MATERIALS AND METHODS

Animals and Treatments
All animals were handled in accordance with the NIH guidelines for the humane care of laboratory animals. Male BALB/C AnNcrj mice (Bio Genomics, Inc., Charles River Technology, Gapyung-Gun, Gyeonggi-Do, Korea) weighing about 25 g were maintained on a 12 : 12 h light : dark cycle and fed ad libitum. They were adapted to these conditions for 2 weeks before the experiment. U.S.A.) was dissolved in sterilized saline (1 mg/kg, i.p.). PAP 9704 is a mixture of Polygala tenuifola, Acorus gramineus, and Poria cocos at a ratio of 1 : 1 : 1 (dry weight).
1) Polygala tenuifolia contains onjisaponins and sugars. 16 ) Acorus gramineus consists mainly of essential oils such as asarone, euasarone and thymol. 17) Poria cocos consists of the polysaccharide pachyman, and the triterpenoids pachymic acid, eburicoic acid, and tumulosic acid. 18) However, a careful review of the literature indicates that the pharmacokinetic properties of this prescription remain to be fully determined. PAP 9704 was supplied by Boryung Pharmaceutical Company, Ansan, Gyeonggi-Do, Korea.
2) Previously we demonstrated the neuroprotective properties of PAP 9704 in vivo. Locomotor Activity Ten minutes after the last treatment with each drug, locomotor activity was measured for 30 min using an automated video-tracking system (Noldus Information Technology, Wagenin, The Netherlands). Eight test boxes (40ϫ40ϫ30 cm high) were operated simultaneously by an IBM computer. Animals were studied individually during locomotion measurement in each test box, where they were adapted for 10 min before starting the experiment. A printout for each session showed the pattern of the ambulatory movements of the test box. The distance traveled in cm by the animals in horizontal locomotor activity was analyzed. Data were collected and analyzed between 0900 and 1700 h. 14, 15) Fos-Related Antigen Immunoreactivity (FRA-IR) Brains were taken 12 h after the final MA treatment and used for immunocytochemical analysis. The coronal sections containing dorsomedial striatum were processed for FRA immunocytochemistry. Prior to overnight incubation with the primary antibody, sections were prewashed in 0.2% Triton X-100 for 15 min, followed by 4% normal goat serum for 20 min. After a 24 h incubation with the primary antiserum, sections were then incubated with a secondary biotinylated antiserum (1 : 800 dilution) for 1 h. Sections were always washed three times with PBS (pH 7.4) between each incubation step. The avidin-biotin complex method (ABC Kits, Vector Laboratories, Inc.) with 3,3Ј-diaminobenzidine tetrahydrochloride as the chromogen was used to visualize immunoreactive cells. The FRA antibody was used at 1 : 2000 as the optimal dilution. The FRA-IR in the striatum was calculated using image analysis systems with a polaroid digital microscopic camera (Optimas version 6.2). 14, 15, 19) The antibody has been characterized, 20) and has been published elsewhere.
12-15,19,21)
Statistical Analysis The significance of these effects was tested using analyses of variance (ANOVA). Differences between the group means were analyzed with Duncan's new multiple range (DMR) test with aϭ0.05. Changes in body weight were analyzed using ANOVA for repeated measures.
To assess the relationship between FRA induction and adenosine receptor antagonism, correlations were estimated and then tested to determine whether they differed from zero. 22) RESULTS AND DISCUSSION (Fig. 1A) . Neither adenosine receptor antagonists nor PAP 9704 significantly altered locomotor activity in mice. Adenosine antagonists at the doses used in this study did not significantly affect MA induced-locomotor activity at However, CPT and ALX failed to alter the effects of PAP 9704 (Fig. 2) .
In this study, we demonstrated that MA-induced increases in locomotor activity are related to corresponding FRA-IR in the mouse striatum, and that PAP 9704 attenuates these effects of MA, at least in part, via adenosine A 2A receptor stimulation. Our data provide interesting functional clues to the relationship between striatal FRA-IR and behavioral features. It has been recognized that the striatal complex is the primary site of the behavioral effect of chronic psychostimulant administration. 12, 13) For example, chronic psychostimulant administration induces expression of chronic FRA-IR in the striatal complex, while FRA-IR is not induced significantly by acute administration. 23, 24) Therefore, FRA appeared to be the transcriptional mediator underlying some of the longlasting biochemical adaptations of MA. Although the nucleus accumbens is more sensitive to some of the effects of neurostimulants than is the striatum during a course of chronic exposure, 13, 14) PAP 9704-induced reduction in FRA-IR increases was more pronounced in the striatum than in the nucleus accumbens (data not shown) in this study.
In our preliminary study, we found that each constituent (Polygala tenuifola, Acorus gramineus or Poria cocos) in the PAP 9704 fails to significantly attenuate locomotor facilitation induced by repeated treatment with MA (data not shown), 5) although polygalasaponins from Polygala tenuifolia and water extract of Acorus gramineus show central inhibitory effects on response induced by a single injection of apomorphine, pentylenetetrazole, cocaine or MK-801. 25, 26) Therefore, it remains to be further characterized what components are responsible for the mechanism of actions of PAP 9704.
It is suggested that both adenosine A 1 and A 2A receptor agonists inhibit MA-induced behavioral effects via different mechanisms. 27) In this study, we found that PAP 9704 shows A 2A receptor agonist-like effects, because PAP 9704-mediated pharmacological action was significantly reversed by the specific A 2A receptor antagonist CSC. Most A 2A receptors are located on striatopallidal GABAergic neurons. Stimulation of these receptors increases the release of GABA in the striatum and globus pallidus and counteracts the D 2 -mediated effects. 11) Similarly, A 2A receptors of cholinergic terminals are activated by A 2A agonist CGS 21680, and then GABAergic neurons might be activated. Further, dopaminergic neurons might be inhibited by activated GABAergic neurons. 28) Therefore, we cannot rule out the possibility that significant reductions in the behavioral effects and FRA-IR induced by PAP 9704 may occur through complex pharmacological interactions between A 2A receptor and DA/GABA receptor complex, although direct evidences should be gathered.
In summary, our results suggest that PAP 9704 attenuates MA-induced hyperactivity, in part, through adenosine A 2A receptor stimulation, although the precise pharmacological mechanisms mediated by PAP 9704 remain to be fully determined. 
